Skip to main content
Clinical Trials/EUCTR2013-003125-28-BE
EUCTR2013-003125-28-BE
Active, not recruiting
Phase 1

Antiplatelet therapy for patients undergoing transcatheter aortic valve implantation - POPular-TAVI

St. Antonius Hospital0 sites1,000 target enrollmentMarch 27, 2017
DrugsPlavix

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
St. Antonius Hospital
Enrollment
1000
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 27, 2017
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patient has provided written informed consent.
  • 1\.Need for long\-term oral anticoagulation;
  • 2\.Patient has provided written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 1000

Exclusion Criteria

  • 1\.Need for long\-term oral anticoagulation.
  • 2\.Drug\-eluting stent implantation within 3 months prior to TAVI procedure.
  • 3\.Bare\-metal stent implantation within 1 month prior to TAVI procedure.
  • 4\.Allergy or intolerance or contraindication to aspirin or clopidogrel.
  • 1\.Drug\-eluting stent implantation within 3 months prior to TAVI procedure.
  • 2\.Bare\-metal stent implantation within 1 month prior to TAVI procedure.
  • 3\.Use of non\-vitamin K oral anticoagulation (NOAC).
  • 4\.Allergy or intolerance or contraindication to OAC or clopidogrel.

Outcomes

Primary Outcomes

Not specified

Similar Trials